Journal article
Longitudinal evaluation of the natural history of amyloid-beta in plasma and brain
Samantha C Burnham, Noelia Fandos, Christopher Fowler, Virginia Perez-Grijalba, Vincent Dore, James D Doecke, Rosita Shishegar, Timothy Cox, Jurgen Fripp, Christopher Rowe, Manuel Sarasa, Colin L Masters, Pedro Pesini, Victor L Villemagne
BRAIN COMMUNICATIONS | OXFORD UNIV PRESS | Published : 2020
Abstract
Plasma amyloid-β peptide concentration has recently been shown to have high accuracy to predict amyloid-β plaque burden in the brain. These amyloid-β plasma markers will allow wider screening of the population and simplify and reduce screening costs for therapeutic trials in Alzheimer’s disease. The aim of this study was to determine how longitudinal changes in blood amyloid-β track with changes in brain amyloid-β. Australian Imaging, Biomarker and Lifestyle study participants with a minimum of two assessments were evaluated (111 cognitively normal, 7 mild cognitively impaired, 15 participants with Alzheimer’s disease). Amyloid-β burden in the brain was evaluated through PET and was expresse..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Funding Acknowledgements
Core funding for the AIBL study was provided by the Commonwealth Scientific and Industrial Research Organization (CSIRO) Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with the Cooperative Research Centre (CRC) for Mental Health, Edith Cowan University (ECU), Mental Health Research institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, Macquarie University, CogState Ltd, Hollywood Private Hospital and Sir Charles Gairdner Hospital. The study also received funding from the National Health and Medical Research Council (NHMRC; 1156891), Dementia Collaborative Research Centres program (DCRC) and McCusker Alzheimer's Research Foundation and operational infrastructure support from the Government of Victoria.